abstract |
The present invention relates to the provision of a novel means for immunological cancer treatment, wherein two different antigen receptors, ie, NKR-P1 (natural killing P1) and Vα24Vβ11, which NKT cells have regarding activation of NKT cells responsible for cancer immunity. The present invention has been found to be completely different from that of the present invention, and provides an anticancer drug using the action of NKR-P1 (natural killing P1) on the activating ability of NKT cells. |